Published in Nat Rev Cancer on August 24, 2011
HECT and RING finger families of E3 ubiquitin ligases at a glance. J Cell Sci (2012) 1.95
BMP signaling controls muscle mass. Nat Genet (2013) 1.68
RING-type E3 ligases: master manipulators of E2 ubiquitin-conjugating enzymes and ubiquitination. Biochim Biophys Acta (2013) 1.64
Protein tyrosine kinase regulation by ubiquitination: critical roles of Cbl-family ubiquitin ligases. Biochim Biophys Acta (2012) 1.39
Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies. J Clin Oncol (2013) 1.30
Cullin-RING Ligases as attractive anti-cancer targets. Curr Pharm Des (2013) 1.19
Threshold-controlled ubiquitination of the EGFR directs receptor fate. EMBO J (2013) 1.11
Limiting the power of p53 through the ubiquitin proteasome pathway. Genes Dev (2014) 1.10
Ubiquitin-dependent sorting in endocytosis. Cold Spring Harb Perspect Biol (2014) 1.10
Spotlight on the role of COP1 in tumorigenesis. Nat Rev Cancer (2012) 1.06
USP15 stabilizes MDM2 to mediate cancer-cell survival and inhibit antitumor T cell responses. Nat Immunol (2014) 1.06
CRL1-FBXO11 promotes Cdt2 ubiquitylation and degradation and regulates Pr-Set7/Set8-mediated cellular migration. Mol Cell (2013) 1.05
Understanding cullin-RING E3 biology through proteomics-based substrate identification. Mol Cell Proteomics (2012) 1.05
The Role of Elongin BC-Containing Ubiquitin Ligases. Front Oncol (2012) 1.04
Structure-Function Of The Tumor Suppressor BRCA1. Comput Struct Biotechnol J (2012) 1.02
Proteome wide purification and identification of O-GlcNAc-modified proteins using click chemistry and mass spectrometry. J Proteome Res (2013) 1.02
The APC/C Ubiquitin Ligase: From Cell Biology to Tumorigenesis. Front Oncol (2012) 1.01
Regulation of ERBB3/HER3 signaling in cancer. Oncotarget (2014) 1.00
Functional characterization of Anaphase Promoting Complex/Cyclosome (APC/C) E3 ubiquitin ligases in tumorigenesis. Biochim Biophys Acta (2014) 1.00
Proteolysis of MOB1 by the ubiquitin ligase praja2 attenuates Hippo signalling and supports glioblastoma growth. Nat Commun (2013) 0.99
Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressor. Cancer Cell (2014) 0.99
A fast workflow for identification and quantification of proteomes. Mol Cell Proteomics (2013) 0.98
Targeting Cdc20 as a novel cancer therapeutic strategy. Pharmacol Ther (2015) 0.97
The Colossus of ubiquitylation: decrypting a cellular code. Mol Cell (2013) 0.96
Senescence-inducing stress promotes proteolysis of phosphoglycerate mutase via ubiquitin ligase Mdm2. J Cell Biol (2014) 0.95
Regulation of TGF-β signal transduction by mono- and deubiquitylation of Smads. FEBS Lett (2012) 0.95
Functional characterization of SAG/RBX2/ROC2/RNF7, an antioxidant protein and an E3 ubiquitin ligase. Protein Cell (2012) 0.95
The ubiquitin ligase Nedd4-1 participates in denervation-induced skeletal muscle atrophy in mice. PLoS One (2012) 0.94
E3 ubiquitin ligase-mediated regulation of bone formation and tumorigenesis. Cell Death Dis (2013) 0.94
Role of p97/VCP (Cdc48) in genome stability. Front Genet (2013) 0.94
Ubiquitylation in immune disorders and cancer: from molecular mechanisms to therapeutic implications. EMBO Mol Med (2012) 0.94
Regulation of ubiquitination-mediated protein degradation by survival kinases in cancer. Front Oncol (2012) 0.93
The ubiquitin-proteasome system and signal transduction pathways regulating Epithelial Mesenchymal transition of cancer. J Biomed Sci (2012) 0.93
Targeting the ubiquitin pathway for cancer treatment. Biochim Biophys Acta (2014) 0.93
Pirh2 RING-finger E3 ubiquitin ligase: its role in tumorigenesis and cancer therapy. FEBS Lett (2012) 0.92
Regulation of the CRL4(Cdt2) ubiquitin ligase and cell-cycle exit by the SCF(Fbxo11) ubiquitin ligase. Mol Cell (2013) 0.92
OTUB1 inhibits the ubiquitination and degradation of FOXM1 in breast cancer and epirubicin resistance. Oncogene (2015) 0.92
Regulation of APC/C-Cdh1 and its function in neuronal survival. Mol Neurobiol (2012) 0.91
JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms. JAKSTAT (2013) 0.91
Put a RING on it: regulation and inhibition of RNF8 and RNF168 RING finger E3 ligases at DNA damage sites. Front Genet (2013) 0.91
Neddylation and deneddylation in cardiac biology. Am J Cardiovasc Dis (2014) 0.90
A hypoxia-responsive TRAF6-ATM-H2AX signalling axis promotes HIF1α activation, tumorigenesis and metastasis. Nat Cell Biol (2016) 0.90
Nkx6.1 regulates islet β-cell proliferation via Nr4a1 and Nr4a3 nuclear receptors. Proc Natl Acad Sci U S A (2014) 0.89
Versatile roles of k63-linked ubiquitin chains in trafficking. Cells (2014) 0.88
Retracted Metastasis-associated protein 1 drives tumor cell migration and invasion through transcriptional repression of RING finger protein 144A. J Biol Chem (2011) 0.88
Inhibition of redox/Fyn/c-Cbl pathway function by Cdc42 controls tumour initiation capacity and tamoxifen sensitivity in basal-like breast cancer cells. EMBO Mol Med (2013) 0.88
Regulation of the protein stability of EMT transcription factors. Cell Adh Migr (2014) 0.88
Cbl exposes its RING finger. Nat Struct Mol Biol (2012) 0.87
Genetically engineered mouse models for functional studies of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases. Cell Res (2013) 0.87
Multi-analyte network markers for tumor prognosis. PLoS One (2012) 0.86
E3 ubiquitin ligase Cbl-b in innate and adaptive immunity. Cell Cycle (2014) 0.86
Arsenite binds to the RING finger domains of RNF20-RNF40 histone E3 ubiquitin ligase and inhibits DNA double-strand break repair. J Am Chem Soc (2014) 0.85
Cellular senescence and protein degradation: breaking down cancer. Cell Cycle (2014) 0.85
Regulation of hematopoietic stem cell fate by the ubiquitin proteasome system. Trends Immunol (2012) 0.84
Cezanne (OTUD7B) regulates HIF-1α homeostasis in a proteasome-independent manner. EMBO Rep (2014) 0.84
Cbl-c ubiquitin ligase activity is increased via the interaction of its RING finger domain with a LIM domain of the paxillin homolog, Hic 5. PLoS One (2012) 0.84
SCF(β-TRCP)-mediated degradation of NEDD4 inhibits tumorigenesis through modulating the PTEN/Akt signaling pathway. Oncotarget (2014) 0.83
Biological influence of Hakai in cancer: a 10-year review. Cancer Metastasis Rev (2012) 0.83
PML Degradation: Multiple Ways to Eliminate PML. Front Oncol (2013) 0.82
Targeting ubiquitination for cancer therapies. Future Med Chem (2015) 0.82
When ubiquitin meets NF-κB: a trove for anti-cancer drug development. Curr Pharm Des (2013) 0.81
Domain organization of XAF1 and the identification and characterization of XIAP(RING) -binding domain of XAF1. Protein Sci (2012) 0.81
Regulation of GATA-binding protein 2 levels via ubiquitin-dependent degradation by Fbw7: involvement of cyclin B-cyclin-dependent kinase 1-mediated phosphorylation of THR176 in GATA-binding protein 2. J Biol Chem (2015) 0.81
Hepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genes. World J Gastroenterol (2016) 0.81
F-box protein Fbxl18 mediates polyubiquitylation and proteasomal degradation of the pro-apoptotic SCF subunit Fbxl7. Cell Death Dis (2015) 0.80
Control of developmentally primed erythroid genes by combinatorial co-repressor actions. Nat Commun (2015) 0.80
SAG/RBX2 is a novel substrate of NEDD4-1 E3 ubiquitin ligase and mediates NEDD4-1 induced chemosensitization. Oncotarget (2014) 0.80
BAP1 promotes breast cancer cell proliferation and metastasis by deubiquitinating KLF5. Nat Commun (2015) 0.80
ETS2 and Twist1 promote invasiveness of Helicobacter pylori-infected gastric cancer cells by inducing Siah2. Biochem J (2016) 0.79
CRL3IBTK Regulates the Tumor Suppressor Pdcd4 through Ubiquitylation Coupled to Proteasomal Degradation. J Biol Chem (2015) 0.79
The Ubiquitin System and Kaposi's Sarcoma-Associated Herpesvirus. Front Microbiol (2012) 0.79
Cbl-family ubiquitin ligases and their recruitment of CIN85 are largely dispensable for epidermal growth factor receptor endocytosis. Int J Biochem Cell Biol (2014) 0.79
Human papillomavirus type 16 E7 oncoprotein inhibits the anaphase promoting complex/cyclosome activity by dysregulating EMI1 expression in mitosis. Virology (2013) 0.79
Ubiquitination-induced fluorescence complementation (UiFC) for detection of K48 ubiquitin chains in vitro and in live cells. PLoS One (2013) 0.79
Regulation of TGF-β signaling, exit from the cell cycle, and cellular migration through cullin cross-regulation: SCF-FBXO11 turns off CRL4-Cdt2. Cell Cycle (2013) 0.79
Deregulation of F-box proteins and its consequence on cancer development, progression and metastasis. Semin Cancer Biol (2015) 0.78
Enigma prevents Cbl-c-mediated ubiquitination and degradation of RETMEN2A. PLoS One (2014) 0.78
Prp19 facilitates invasion of hepatocellular carcinoma via p38 mitogen-activated protein kinase/twist1 pathway. Oncotarget (2016) 0.78
Parallel Regulation of von Hippel-Lindau Disease by pVHL-Mediated Degradation of B-Myb and Hypoxia-Inducible Factor α. Mol Cell Biol (2016) 0.78
Establishment of a Wheat Cell-Free Synthesized Protein Array Containing 250 Human and Mouse E3 Ubiquitin Ligases to Identify Novel Interaction between E3 Ligases and Substrate Proteins. PLoS One (2016) 0.78
praja2 regulates KSR1 stability and mitogenic signaling. Cell Death Dis (2016) 0.77
Induction of c-Cbl contributes to anti-cancer effects of HDAC inhibitor in lung cancer. Oncotarget (2015) 0.77
Participation of proteasome-ubiquitin protein degradation in autophagy and the activation of AMP-activated protein kinase. Cell Signal (2015) 0.77
Mutations of c-Cbl in myeloid malignancies. Oncotarget (2015) 0.76
Regulation of cancer stem cells by RING finger ubiquitin ligases. Stem Cell Investig (2014) 0.76
Characterization of the Arabidopsis thaliana E3 ubiquitin-ligase AtSINAL7 and identification of the ubiquitination sites. PLoS One (2013) 0.76
Structural basis for the indispensable role of a unique zinc finger motif in LNX2 ubiquitination. Oncotarget (2015) 0.76
Transforming growth factor β1 increases p27 levels via synthesis and degradation mechanisms in the hyperproliferative gastric epithelium in rats. PLoS One (2014) 0.75
Genome-wide identification and gene expression profiling of ubiquitin ligases for endoplasmic reticulum protein degradation. Sci Rep (2016) 0.75
RNF122 suppresses antiviral type I interferon production by targeting RIG-I CARDs to mediate RIG-I degradation. Proc Natl Acad Sci U S A (2016) 0.75
Fbxo45 joins the 'Par-4'ty in controlling apoptosis of cancer cells. Cell Death Differ (2014) 0.75
DCAF4L2 promotes colorectal cancer invasion and metastasis via mediating degradation of NFκb negative regulator PPM1B. Am J Transl Res (2016) 0.75
OLA1 in centrosome biology alongside the BRCA1/BARD1 complex: looking beyond centrosomes. Mol Cell (2014) 0.75
TRIM71 suppresses tumorigenesis via modulation of Lin28B-let-7-HMGA2 signaling. Oncotarget (2016) 0.75
Regulation of XIAP Turnover Reveals a Role for USP11 in Promotion of Tumorigenesis. EBioMedicine (2016) 0.75
Foiling IDOL to Help Control Cholesterol. Circ Res (2016) 0.75
A Comprehensive Guide to the MAGE Family of Ubiquitin Ligases. J Mol Biol (2017) 0.75
Scaffold protein FHL2 facilitates MDM2-mediated degradation of IER3 to regulate proliferation of cervical cancer cells. Oncogene (2016) 0.75
Epigallocatechin-3-gallate(EGCG) suppresses melanoma cell growth and metastasis by targeting TRAF6 activity. Oncotarget (2016) 0.75
De novo PHIP-predicted deleterious variants are associated with developmental delay, intellectual disability, obesity, and dysmorphic features. Cold Spring Harb Mol Case Stud (2016) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Wnt/beta-catenin signaling in development and disease. Cell (2006) 30.09
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A (1996) 29.54
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 26.32
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 24.42
Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science (2001) 23.83
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (1999) 23.45
HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science (2001) 22.06
Mdm2 promotes the rapid degradation of p53. Nature (1997) 21.26
C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell (2001) 19.75
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature (2005) 19.13
Regulation of p53 stability by Mdm2. Nature (1997) 18.20
Blinded by the Light: The Growing Complexity of p53. Cell (2009) 17.75
Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature (1992) 17.40
Oncogenic kinase signalling. Nature (2001) 16.30
Identification of the von Hippel-Lindau disease tumor suppressor gene. Science (1993) 11.95
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett (1997) 11.19
The anaphase promoting complex/cyclosome: a machine designed to destroy. Nat Rev Mol Cell Biol (2006) 10.76
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature (1995) 10.18
Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet (1994) 10.14
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet (2010) 9.72
Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol (2000) 9.16
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature (1995) 8.68
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet (2010) 8.41
The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell (1998) 8.33
Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell (1997) 8.28
FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer (2008) 7.93
Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases. Cell (2000) 7.82
Brca1 controls homology-directed DNA repair. Mol Cell (1999) 7.82
The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science (1999) 7.60
Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature (2009) 7.37
RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc Natl Acad Sci U S A (1999) 7.32
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell (2007) 7.24
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell (2007) 7.10
Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem (2000) 6.92
Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell (1999) 6.79
Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer (2006) 6.76
Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science (1999) 6.38
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell (2002) 6.32
Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer (2008) 6.10
Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell (1997) 5.92
Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol (1999) 5.78
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A (1996) 5.69
Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med (2004) 5.48
HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell (2005) 5.47
c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev (1998) 5.31
Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science (2000) 5.22
Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol (2003) 5.14
The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol (2010) 5.04
Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex. Nat Cell Biol (2002) 5.02
Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell (2003) 4.96
How the fanconi anemia pathway guards the genome. Annu Rev Genet (2009) 4.94
Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science (1995) 4.93
The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair. Science (2009) 4.85
Tumour suppression by the human von Hippel-Lindau gene product. Nat Med (1995) 4.71
FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med (2007) 4.59
The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J Biol Chem (2001) 4.51
Differential regulation of EGF receptor internalization and degradation by multiubiquitination within the kinase domain. Mol Cell (2006) 4.36
Structure of a BRCA1-BARD1 heterodimeric RING-RING complex. Nat Struct Biol (2001) 4.15
The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell (2002) 4.13
Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature (2000) 4.08
Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J Biol Chem (2004) 4.05
Cbl-b regulates the CD28 dependence of T-cell activation. Nature (2000) 3.89
Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A (1996) 3.88
Signaling to p53: ribosomal proteins find their way. Cancer Cell (2009) 3.84
Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature (2009) 3.80
BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol (2009) 3.79
Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. Nature (2002) 3.78
Siah2 regulates stability of prolyl-hydroxylases, controls HIF1alpha abundance, and modulates physiological responses to hypoxia. Cell (2004) 3.77
The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci U S A (1997) 3.75
SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. Nat Genet (2011) 3.74
Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood (2009) 3.69
The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress. Nature (2009) 3.62
Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet (2010) 3.57
Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc Natl Acad Sci U S A (2002) 3.54
A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease necessary for DNA interstrand crosslink repair. Mol Cell (2010) 3.51
E2F-dependent accumulation of hEmi1 regulates S phase entry by inhibiting APC(Cdh1). Nat Cell Biol (2002) 3.46
Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol (2005) 3.44
BRCA1 ubiquitinates its phosphorylation-dependent binding partner CtIP. Genes Dev (2006) 3.44
Identification of KIAA1018/FAN1, a DNA repair nuclease recruited to DNA damage by monoubiquitinated FANCD2. Cell (2010) 3.43
Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci U S A (1999) 3.43
Deficiency of FANCD2-associated nuclease KIAA1018/FAN1 sensitizes cells to interstrand crosslinking agents. Cell (2010) 3.37
Emi1 is a mitotic regulator that interacts with Cdc20 and inhibits the anaphase promoting complex. Cell (2001) 3.36
Genomic stability and tumour suppression by the APC/C cofactor Cdh1. Nat Cell Biol (2008) 3.31
Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol (2010) 3.30
The Cbl interactome and its functions. Nat Rev Mol Cell Biol (2005) 3.27
Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science (2006) 3.26
Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc Natl Acad Sci U S A (2001) 3.24
The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev (1999) 3.17
The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol (2010) 3.08
Parc: a cytoplasmic anchor for p53. Cell (2003) 3.06
MDM2 interacts with MDMX through their RING finger domains. FEBS Lett (1999) 2.98
Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci U S A (2001) 2.98
BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet (2001) 2.98
Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene (2000) 2.84
SCFbeta-TRCP controls oncogenic transformation and neural differentiation through REST degradation. Nature (2008) 2.84
Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyubiquitylation. J Biol Chem (2003) 2.77
Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. Immunity (2004) 2.76
HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc Natl Acad Sci U S A (2003) 2.73
Mind bomb is a ubiquitin ligase that is essential for efficient activation of Notch signaling by Delta. Dev Cell (2003) 4.30
SINAT5 promotes ubiquitin-related degradation of NAC1 to attenuate auxin signals. Nature (2002) 2.94
Structural basis for ubiquitin recognition and autoubiquitination by Rabex-5. Nat Struct Mol Biol (2006) 2.85
Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res (2007) 2.60
The activity of a human endoplasmic reticulum-associated degradation E3, gp78, requires its Cue domain, RING finger, and an E2-binding site. Proc Natl Acad Sci U S A (2006) 2.41
A conserved catalytic residue in the ubiquitin-conjugating enzyme family. EMBO J (2003) 2.37
Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell (2005) 2.17
Ubiquitin ligases, critical mediators of endoplasmic reticulum-associated degradation. Semin Cell Dev Biol (2007) 2.13
BTBD1 and BTBD2 colocalize to cytoplasmic bodies with the RBCC/tripartite motif protein, TRIM5delta. Exp Cell Res (2003) 2.06
Nedd4 mediates agonist-dependent ubiquitination, lysosomal targeting, and degradation of the beta2-adrenergic receptor. J Biol Chem (2008) 2.00
HECT and RING finger families of E3 ubiquitin ligases at a glance. J Cell Sci (2012) 1.95
Allosteric activation of E2-RING finger-mediated ubiquitylation by a structurally defined specific E2-binding region of gp78. Mol Cell (2009) 1.83
The ubiquitin ligase gp78 promotes sarcoma metastasis by targeting KAI1 for degradation. Nat Med (2007) 1.81
WW domain HECT E3s target Cbl RING finger E3s for proteasomal degradation. J Biol Chem (2003) 1.79
Differences in the tumor microenvironment between African-American and European-American breast cancer patients. PLoS One (2009) 1.72
The Rab5 guanine nucleotide exchange factor Rabex-5 binds ubiquitin (Ub) and functions as a Ub ligase through an atypical Ub-interacting motif and a zinc finger domain. J Biol Chem (2006) 1.68
CAIR-1/BAG-3 abrogates heat shock protein-70 chaperone complex-mediated protein degradation: accumulation of poly-ubiquitinated Hsp90 client proteins. J Biol Chem (2003) 1.67
Ubiquitin-proteasome-dependent degradation of a mitofusin, a critical regulator of mitochondrial fusion. Mol Biol Cell (2008) 1.66
RING-type E3 ligases: master manipulators of E2 ubiquitin-conjugating enzymes and ubiquitination. Biochim Biophys Acta (2013) 1.64
The Unfolded Protein Response, Degradation from Endoplasmic Reticulum and Cancer. Genes Cancer (2010) 1.55
Malfolded protein structure and proteostasis in lung diseases. Am J Respir Crit Care Med (2014) 1.47
Stress-induced phosphorylation and proteasomal degradation of mitofusin 2 facilitates mitochondrial fragmentation and apoptosis. Mol Cell (2012) 1.46
RING finger ubiquitin protein ligases: implications for tumorigenesis, metastasis and for molecular targets in cancer. Semin Cancer Biol (2003) 1.42
Regulating the p53 system through ubiquitination. Oncogene (2004) 1.39
Overexpression of the tumor autocrine motility factor receptor Gp78, a ubiquitin protein ligase, results in increased ubiquitinylation and decreased secretion of apolipoprotein B100 in HepG2 cells. J Biol Chem (2003) 1.37
Ubiquitin charging of human class III ubiquitin-conjugating enzymes triggers their nuclear import. J Cell Biol (2004) 1.33
Serine residues in the cytosolic tail of the T-cell antigen receptor alpha-chain mediate ubiquitination and endoplasmic reticulum-associated degradation of the unassembled protein. J Biol Chem (2010) 1.18
E6AP mediates regulated proteasomal degradation of the nuclear receptor coactivator amplified in breast cancer 1 in immortalized cells. Cancer Res (2006) 1.08
A mutation associated with CMT2A neuropathy causes defects in Fzo1 GTP hydrolysis, ubiquitylation, and protein turnover. Mol Biol Cell (2009) 1.08
Inositol 1,4,5-trisphosphate receptor ubiquitination is mediated by mammalian Ubc7, a component of the endoplasmic reticulum-associated degradation pathway, and is inhibited by chelation of intracellular Zn2+. J Biol Chem (2003) 1.06
Identification of developmentally expressed proteins that functionally interact with Nedd4 ubiquitin ligase. J Biol Chem (2001) 1.06
Allosteric regulation of E2:E3 interactions promote a processive ubiquitination machine. EMBO J (2013) 1.05
Targeting of gp78 for ubiquitin-mediated proteasomal degradation by Hrd1: cross-talk between E3s in the endoplasmic reticulum. Biochem Biophys Res Commun (2009) 1.03
A Ubc7p-binding domain in Cue1p activates ER-associated protein degradation. J Cell Sci (2009) 1.01
Dissecting the diverse functions of the metastasis suppressor CD82/KAI1. FEBS Lett (2011) 0.98
Sequential requirements for the GTPase domain of the mitofusin Fzo1 and the ubiquitin ligase SCFMdm30 in mitochondrial outer membrane fusion. J Cell Sci (2011) 0.97
Multiple roles of Rbx1 in the VBC-Cul2 ubiquitin ligase complex. Genes Cells (2005) 0.96
Expression, purification, and properties of the Ubc4/5 family of E2 enzymes. Methods Enzymol (2005) 0.96
A structurally unique E2-binding domain activates ubiquitination by the ERAD E2, Ubc7p, through multiple mechanisms. Mol Cell (2013) 0.95
Differential regulation of HMG-CoA reductase and Insig-1 by enzymes of the ubiquitin-proteasome system. Mol Biol Cell (2012) 0.95
Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system. Proc Natl Acad Sci U S A (2010) 0.94
EGF receptor-independent action of TGF-alpha protects Naked2 from AO7-mediated ubiquitylation and proteasomal degradation. Proc Natl Acad Sci U S A (2008) 0.93
Ubiquitylation in ERAD: reversing to go forward? PLoS Biol (2011) 0.92
Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2. Mol Cancer Ther (2008) 0.92
Identification of inhibitors for MDM2 ubiquitin ligase activity from natural product extracts by a novel high-throughput electrochemiluminescent screen. J Biomol Screen (2008) 0.89
Compact Parkin only: insights into the structure of an autoinhibited ubiquitin ligase. EMBO J (2013) 0.86
Expression and evaluation of RING finger proteins. Methods Enzymol (2005) 0.85
Studies of the ubiquitin proteasome system. Curr Protoc Cell Biol (2006) 0.84
Promiscuous interactions of gp78 E3 ligase CUE domain with polyubiquitin chains. Structure (2012) 0.84
Working on a chain: E3s ganging up for ubiquitylation. Nat Cell Biol (2010) 0.82
Discovery of new pyridoacridine alkaloids from Lissoclinum cf. badium that inhibit the ubiquitin ligase activity of Hdm2 and stabilize p53. Bioorg Med Chem (2008) 0.82
A ubiquitin-binding rhomboid protease aimed at ERADication. Dev Cell (2012) 0.76
Cullin RING ligases: glommed by glomulin. Mol Cell (2012) 0.75
Ubiquitin and drug discovery: challenges and opportunities. Cell Biochem Biophys (2013) 0.75